North America onychomycosis treatment market is projected to grow by 7.2% annually in the forecast period and reach $2,111.2 million by 2031, driven by the increasing prevalence of chronic medical ailments, the growing geriatric population, improved therapies and preventative solutions, and the rising healthcare expenditure.
Highlighted with 21 tables and 36 figures, this 87-page report “North America Onychomycosis Treatment Market 2021-2031 by Onychomycosis Type (Distal Subungual, White Superficial, Proximal Subungual, Candidal, Others), Treatment Type (Drug Treatment, Laser Therapy, Photodynamic Therapy, Others), Distribution Channel (Hospitals and Clinics, Online Stores, Retail Pharmacies, Others), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America onychomycosis treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and the Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify North America onychomycosis treatment market in every aspect of the classification from perspectives of Onychomycosis Type, Treatment Type, Distribution Channel, and Country.
Based on Onychomycosis Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Distal Subungual Onychomycosis
• White Superficial Onychomycosis
• Proximal Subungual Onychomycosis
• Candidal Onychomycosis
• Other Onychomycosis Types
Based on Treatment Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Drug Treatment
• Laser Therapy
• Photodynamic Therapy
• Other Therapies
By Distribution Channel, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Hospitals and Clinics
• Online Stores
• Retail Pharmacies
• Other Distribution Channels
Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
• Mexico
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Onychomycosis Type, Treatment Type and Distribution Channel over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Bausch Health Companies Inc.
Bayer AG
Cipla Ltd
Dr. Reddys Laboratories Ltd
Galderma SA
GlaxoSmithKline PLC
Johnson & Johnson
Lumenis Ltd
Medimetriks Pharmaceuticals Inc.
Moberg Pharma AB
Novartis AG
Pfizer Inc.
Sanofi SA
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
